NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna® Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

An Updated Biomarker Commons Website

Today, we’ve launched an updated BiomarkerCommons.org website. We’ve kept the clean page style and introduce larger, easier-to-read fonts and a new layout optimized for all your mobile devices.

Biomarker Commons Introduces Digital Memberships

Biomarker Commons launched three-and-a-half years ago with an ambitious goal: curate the growing biomarker industry and track the discovery, development and use of biomarkers. Our business plan was simple: support the site with advertising revenue. Not surprisingly, given the changes to the media industry over the last few years, that plan hasn’t worked out.

Proteome Sciences Announces $2.1m Contract with Thermo Fisher Scientific

Proteome Sciences recently announced its largest contract to date, a technology agreement with Thermo Fisher Scientific, valued at $2.1million by Proteome Sciences, to develop advanced methods to profile changes in key cancer pathways. Proteome Sciences will provide Thermo Fisher with access to its patents covering a three-stage mass spectrometry (MS3) fragmentation methodology to deliver significantly improved analysis and accuracy. Proteome Sciences will receive cash and Thermo Fisher will provide a no-cost lease for mass spectrometry equipment for Proteome Sciences to develop the pathway assays. In addition Proteome Sciences will continue to develop advanced 20 and 30-plex Tandem Mass Tags (TMT®) for Thermo Fisher for the next additions to the TMT® range of tags.

The new MS3 TMT® (three-stage MS Tandem Mass Tag) mass spectrometry technique is a breakthrough mass spectrometry based workflow, enabling mass spectrometers to determine relative quantitation of proteins in multiple samples simultaneously and with improved accuracy.
“We are at a critical juncture toward the development of personalised medicine which requires high-resolution maps of the protein networks regulating disease,” said Dr. Ian Pike, Chief Operating Officer at Proteome Sciences. “The combination of the highest sample multiplexing rates from TMT with the industry-leading Thermo Scientific Orbitrap mass spectrometer enables us to provide an unrivalled platform to investigate subtle but significant changes in the proteome.”
Proteome Sciences will leverage the combined power of TMT® and Orbitrap® technology to develop an expanded range of mass spectrometry assays for the pharmaceutical industry. Through its SysQuant® workflows, Proteome will profile the low-level changes in activity of key cancer signalling pathways to facilitate optimal drug selection across a range of solid tumours. This will enable clinicians to provide real-time patient management and the ability, for the first time, to deliver truly personalised medicine.

“Life sciences researchers today need to perform high-quality relative quantitation of many samples quickly,” said Ian Jardine, Chief Technology Officer, Chromatography and Mass Spectrometry, Thermo Fisher Scientific. “MS3 TMT® technology greatly improves quantitative accuracy and throughput, while Orbitrap® technology dramatically increases depth and quality of data. This agreement offers customers a new paradigm in proteomics research.”
“Our agreement with Thermo Fisher sets a new benchmark to establish and apply novel diagnostic and prognostic strategies in healthcare management,” said Christopher Pearce, Chief Executive of Proteome Sciences. “It has long been our goal to provide clinicians the tools they need to provide early diagnosis of disease and better match molecular targeting medicines to the most likely responders. The output from this agreement should have a profound positive impact on the lives of large numbers of patients suffering from chronic diseases and, at the same time, provide considerable economic benefits to the health care system.”

Source: Proteome Sciences

8 Questions about Biomarker Commons

Biomarker Commons launched just over three years ago with the goal of aggregating the latest biomarker and personalized medicine news.

Now, we really need your feedback. We’ve got 8 simple questions that should take you less than 5 minutes to complete. Please let us know how we’ve been doing and what we can do to improve our service.